Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aurora CannabisACB -0.49%58 3-Year EPS without NRI Growth Rate is 61.20% as of Jun. 2026. GuruFocus rates ACB with a GF Score™ of 58/100 and a GF Value™ of $3.89 (Fairly Valued). The stock has 2 warning signs investors should review. Among 785 Drug Manufacturers companies, Aurora Cannabis ranks better than 92.23% on this metric.
During the past 12 months, Aurora Cannabis's average EPS without NRI Growth Rate was -775.30% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 61.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Aurora Cannabis was 77.30% per year. The lowest was -112.90% per year. And the median was -19.25% per year.
Aurora Cannabis (NAS:ACB) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Aurora Cannabis 3-Year EPS without NRI Growth Rate Related Terms
ACB vs ZTS: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aurora Cannabis's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurora Cannabis 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aurora Cannabis's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Aurora Cannabis's 3-Year EPS without NRI Growth Rate falls into.
Aurora Cannabis 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 61.20% mean?
Aurora Cannabis (ACB) has a 3-Year EPS without NRI Growth Rate of 61.20% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Aurora Cannabis and its competitors. According to the industry distribution chart, Aurora Cannabis ranks #61 out of 785 companies in the Drug Manufacturers industry, placing it in the top 7.8%.
Is Aurora Cannabis' 3-Year EPS without NRI Growth Rate too high?
Aurora Cannabis' current 3-Year EPS without NRI Growth Rate is 61.20%. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.90. Aurora Cannabis' value of 61.20% is 518.2% above this industry median. Based on the distribution chart, Aurora Cannabis ranks #61 out of 785 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Aurora Cannabis has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aurora Cannabis' 3-Year EPS without NRI Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Aurora Cannabis ranks #61 out of 785 companies for 3-Year EPS without NRI Growth Rate. This places Aurora Cannabis in the top 8% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 9.90. Aurora Cannabis' value of 61.20% is 518.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.90, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurora Cannabis's current 3-Year EPS without NRI Growth Rate of 61.20% is 518.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Aurora Cannabis and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurora Cannabis's current 3-Year EPS without NRI Growth Rate is 61.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurora Cannabis stock overvalued right now?
Based on GuruFocus' analysis, Aurora Cannabis (ACB) is currently considered Fairly Valued. The stock's GF Value™ is $3.89, compared to a current price of $4.04 — trading 3.9% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 61.20% and 518.2% above the Drug Manufacturers industry median of 9.90. Aurora Cannabis' overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Aurora Cannabis (ACB), the current 3-Year EPS without NRI Growth Rate is 61.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurora Cannabis (ACB) Overvalued in 2026?
Based on GuruFocus' analysis, Aurora Cannabis stock appears to be overvalued.
The current stock price of $4.04 is trading 3.9% above its estimated GF Value™ of $3.89.
GuruFocus considers Aurora Cannabis to be Fairly Valued.
Key valuation signals for ACB:
3-Year EPS without NRI Growth Rate: 61.20%
GF Value™: $3.89 vs. price of $4.04 (3.9% above fair value)
Industry Position: 518.2% above the Drug Manufacturers median (#61 of 785)
No single metric tells the full story. See the ACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurora Cannabis Inc is focused on the production, distribution, and sale of cannabis products in Canada and internationally. The Company conducts the production, distribution, and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; the production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and the distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Its segments are Canadian Cannabis CGU, European Cannabis CGU, Australia Cannabis CGU, and New Zealand Cannabis CGU, with Canada generating majority revenue.
58GF Score
Get the complete analysis for ACB
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACB has been successfully added to your 
